SLAMF9
SLAM family member 9
Also known as: CD2F-10, CD84-H1, SF2001, SLAF9_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q96A28
- Gene
- SLAMF9
- Ensembl
- ENSG00000162723
- Chromosome
- 1
- Canonical length
- 289 aa
- Protein class
- Predicted membrane proteins
OverviewNCBI Gene
This gene encodes a member of the signaling lymphocytic activation molecule family. The encoded protein is a cell surface molecule that consists of two extracellular immunoglobulin domains, a transmembrane domain and a short cytoplasmic tail that lacks the signal transduction motifs found in other family members. Alternative splicing results in multiple transcript variants.[provided by RefSeq, Apr 2009]
Canonical amino-acid sequenceUniProt
289 residues, UniProt reviewed canonical sequence.
>Q96A28|SLAMF9
1 MCAFPWLLLL LLLQEGSQRR LWRWCGSEEV VAVLQESISL PLEIPPDEEV ENIIWSSHKS
61 LATVVPGKEG HPATIMVTNP HYQGQVSFLD PSYSLHISNL SWEDSGLYQA QVNLRTSQIS
121 TMQQYNICVY RWLSEPQITV NFESSGEGAC SMSLVCSVEK AGMDMTYSWL SRGDSTYTFH
181 EGPVLSTSWR PGDSALSYTC RANNPISNVS SCPIPDGPFY ADPNYASEKP STAFCLLAKG
241 LLIFLLLVIL AMGLWVIRVQ KRHKMPRMKK LMRNRMKLRK EAKPGSSPALocalizationUniProt · AlphaFold · HPA
Whether an antibody against SLAMF9 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.4
- Highest tissue expression
- 0.5 nTPM
Expression across tissuesHPA
Tissue
- adipose tissue: 0.5 nTPM
- liver: 0.5 nTPM
- testis: 0.5 nTPM
- appendix: 0.4 nTPM
- bone marrow: 0.2 nTPM
- fallopian tube: 0.2 nTPM
Single-cell type
- late spermatids: 64 nCPM
- cdc: 22 nCPM
- early spermatids: 13 nCPM
- macrophages: 4.9 nCPM
- hepatocytes: 3.5 nCPM
- gastric chief cells: 3.3 nCPM
Immune cell
- myeloid DC: 2.1 nTPM
- neutrophil: 0.2 nTPM
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
Brain region
- thalamus: 0.5 nTPM
- white matter: 0.4 nTPM
- cerebral cortex: 0.2 nTPM
- hypothalamus: 0.2 nTPM
- medulla oblongata: 0.2 nTPM
- pons: 0.2 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.28
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.11
- DepMap mean gene effect
- -0.18
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads SLAMF9 as an antibody target. Whether an autoantibody or antibody against SLAMF9 could matter depends on whether native SLAMF9 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
SLAMF9 is annotated at the cell surface, where native SLAMF9 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label SLAMF9 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...